Skip to main content
NCBI home page
PLOS One logoLink to PLOS One
. 2023 Apr 6;18(4):e0283827. doi: 10.1371/journal.pone.0283827

Peripheral nervous system involvement associated with COVID-19. A systematic review of literature

Andreea-Raluca Hanganu 1,2,*, Alexandru Constantin 3,4, Elena-Sonia Moise 5, Cristian-Mihail Niculae 1,2, Ioana Diana Olaru 6,7, Cristian Băicuș 1,3, Adriana Hristea 1,2
Editor: Victor Daniel Miron8
PMCID: PMC10079054  PMID: 37023030

Abstract

There is increasing evidence of both central and peripheral nervous system (PNS) involvement in COVID-19. We conducted this systematic literature review to investigate the characteristics, management and outcomes of patients with PNS, including the types and severity of cranial nerves (CN) involvement. We systematically searched on PubMed for studies reporting adult patients diagnosed with COVID-19 and PNS involvement until July 2021. From 1670 records, 225 articles matched the inclusion criteria, with a total of 1320 neurological events, in 1004 patients. There were 805 (61%) CN, 350 (26.5%) PNS, and 165 (12.5%) PNS plus CN events. The most frequently involved CN were the facial, vestibulo-cochlear and olfactory nerve in 27.3%, 25.4% and 16.1%, respectively. Guillain-Barre syndrome spectrum was identified in 84.2% of PNS events. We analysed 328 patients reported in 225 articles with CN, PNS, and PNS plus CN involvement. The patients with CN involvement were younger (mean age 46.2±17.1, p = .003), and were more frequently treated as outpatients (p < .001), mostly with glucocorticoids (p < .001). Patients that had PNS with or without CN involvement were more likely to be hospitalized (p < .001), and to receive intravenous immunoglobulins (p = .002) or plasma exchange (p = .002). Patients with CN, PNS, and PNS plus CN had severe COVID -19 disease in 24.8%, 37.3%, 34.9% respectively. The most common neurological outcome was mild/moderate sequelae in patients with CN, PNS, and PNS plus CN in 54.7%, 67.5% and 67.8% respectively (p = .1) and no significant difference was found between the three categories regarding death, disease severity, time from disease onset to neurological symptoms, lack of improvement and complete recovery. CN involvement was the most frequent PNS finding. All three categories of PNS involvement were rather associated to non-severe COVID-19 but it may be an important cause of hospitalization and post COVID-19 sequelae.

Introduction

SARS-CoV-2 is a respiratory virus spread, but more recent studies show that the primary tropism of SARS-CoV-2 is not limited to the respiratory tract. Furthermore, there are increasing reports of cases with nervous system involvement, suggesting neurotropism of the virus [1]. A large variety of nervous system manifestations have been reported, from headache and fatigue to stroke, encephalopathy and coma [2]. In addition to central nervous system (CNS) manifestations, a broad spectrum of peripheral nervous system (PNS) manifestations has been described [2].

The hallmark of PNS involvement in SARS-CoV-2 infection is the Guillain Barré syndrome (GBS) with its most common subtypes: acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), acute motor sensory axonal neuropathy (AMSAN), Miller Fisher syndrome (MFS), pharyngeal-cervical-brachial GBS (PCB-GBS). To date most systematic literature reviews on PNS involvement have focused on the GBS spectrum [3]. Given the increasing number of patients with neurological manifestations, this area would deserve more attention.

We conducted this systematic literature review to investigate the characteristics, management and outcomes of patients with PNS involvement in COVID-19, including the GBS spectrum, the CN, mononeuritis, dysautonomia, and other types of PNS manifestations. We structured the review in two parts. The first part describes the peripheral nervous system manifestations associated with COVID-19. In the second part we explored associations between PNS and CN involvement and characteristics of patients with COVID-19. We also aimed to discuss possible mechanisms of the PNS findings.

Methods

Study design and methods

We registered the study protocol in the PROSPERO database with number CRD42021262017. We systematically searched published studies reporting cases of adult patients diagnosed with COVID-19 and PNS involvement that matched our inclusion and exclusion criteria. The search terms were used as keywords and in combination as MeSH terms in order to maximize the output from literature findings Two authors (ARH, AC) searched PUBMED up to July 2021 using the keywords below:

((((covid-19) OR (sars-cov-2)) OR (covid)) OR (covid19)) AND ((((((((((((((((((((((((((((((((((((((mononeuritis) OR (mononeuritis multiplex)) OR (plexopathy)) OR (polyneuropathy)) OR (polyradiculoneuritis)) OR (miller fisher)) OR (peripheral neuropathy)) OR (neuropathy)) OR (neuritis)) OR (polyneuritis))) OR (cranial neuropathy)) OR (olfactory nerve)) OR (optic nerve)) OR (oculomotor nerve)) OR (trochlear nerve)) OR (trigeminal nerve)) OR (abducens nerve)) OR (facial nerve)) OR (vestibulocochlear nerve)) OR (glossopharyngeal nerve)) OR (vagus nerve)) OR (accessory nerve)) OR (hypoglossal nerve)) OR (diplopia)) OR (eyelid ptosis)) OR (strabismus)) OR (facial hypoesthesia)) OR (facial palsy)) OR (facial paresis)) OR (bell’s palsy)) OR (vertigo)) OR (hypoacusis)) OR (dizziness)) OR (dysarthria)) OR (dysphagia)) OR (hypoglossal palsy)) OR (guillain barre))

Using a PICO framework, our target population of interest for this systematic review was adult patients (≥18 years old) diagnosed with COVID-19 (SARS-COV-2 infection confirmed by a RT-PCR or antigen test) who had a new onset of peripheral nervous system manifestations, including CN neuropathies within the six months following the SARS-CoV2 infection, and which were presumed to be associated with COVID-19.

Studies eligibility criteria and data extraction

Inclusion criteria

We used the following inclusion criteria: any English, Spanish or French written articles reporting on at least patient diagnosed with COVID-19 by either a RT-PCR or antigen test that associated a peripheral nervous system or CN neuropathy either at the time of infection or up to 6 months thereafter. We defined and included any of the following peripheral neuropathies: CN neuropathies, motor or sensitive nerve neuropathies, either mononeuropathies or polyneuropathies, Guillain Barré syndrome with all its subtypes and any autonomic nervous system manifestations.

Exclusion criteria

Articles were excluded according to the following criteria: articles reporting only on pediatric cases, those on patients in whom the COVID-19 diagnosis was made clinically or using serological tests, articles reporting neuropathies in patients vaccinated for SARS-CoV-2 within the previous three months in whom the neurological findings could have been attributed to vaccination, articles reporting on patients only with anosmia and/or ageusia that were not clearly stated to be caused by direct nerve involvement, and articles reporting cases of preexisting neuropathies secondary to other causes.

Study eligibility was established by two authors (AF, AC) who initially evaluated the abstracts based on the eligibility criteria. Disagreements were discussed with two other authors (CB, AH). Duplicated reports were excluded. Full text screening was conducted in duplicate based on inclusion and exclusion criteria. Data were abstracted in duplicate by two authors (ARH, AC). The following information was obtained from each study: study type, number of patients included, demographics, level of care (intensive care unit (ICU)/general ward /outpatient), COVID-19 severity, time between the onset of COVID-19 symptoms and that of the neurological manifestations, type of neuropathy, type of nerves involved, neuropathy treatment used, neurologic outcomes.

All articles were included in the qualitative synthesis and articles reporting on individual patient data were included in the quantitative synthesis as summarised in the PRISMA flow chart in Fig 1. A detailed checklist of the PRISMA criteria is available in S1 Fig.

Fig 1. PRISMA flow diagram showing articles selection strategy.

Fig 1

Open in a new tab

Statistical analysis

The descriptive statistical data for categorical variables were presented as numbers/percentages and continuous variables as medians (range) or means ± standard deviation (SD). We used the Shapiro–Wilk test to assess if our numerical data were normally distributed. Ordinal variables and continuous variables for data that significantly deviated from a normal distribution were compared using the Kruskall-Wallis test for ≥ 3 groups. We applied post hoc tests in order to compare the variables separately. The t-test was used for normally distributed continuous variables. Categorical variables were compared among groups using the chi-squared test. A p-value of < .05 was considered statistically significant. We analyzed the collected data using the Statistical Package for Social Sciences (SPSS version 23, IBM Corp., Armonk, NY, USA).

Results

We included in our analysis data provided in 225 studies summing a total of 1320 pooled neurological events, in 1004 patients that presented with both CN involvement and PNS manifestations. In Table 1 we synthesized the data extracted from the case series that did not provide individual data in order to be analyzed.

Table 1. Demographics and characteristics of peripheral nervous system involvement in large case series studies.

Nr. Author No of patients Male sex N (%) COVID disease type PNS CN Diagnosis Treatment Neurological outcome
1 Yaseen et. al. [4] 26 6 (23) Non-severe VIII 26 Audiometry MRI GC 21 partially improved
2 Foresti et. al. [5] 17 11 (65) Severe AIDP 9 V/VII 8 EMG, CSF 15IVIG, 1PLEX 15 improved 1 death
3 Doblan et. al. [6] 135 71 (52.5) 28 severe I 82
II 15
III+IV+VI 19
V 5
VII 93
VIII 52
IX 76
X 28
XI 11		 Clinical No treat 37 incomplete recovery 98 complete recovery
4 Ozdemir et. al. [7] 33 26 (79) NA VII 33 NA NA NA
5 Altundag et. al. [8] 24 10 (42) NA 24I NA NA NA
6 Dhamne et. al. [9] 42 31 (74) 14 severe AIDP 25
AMSAN 9
AIDP+AMSAN 3
PNP 3
12 GBS		 MFS 3
VIII 5
IX+X 1
III+IV+VI 3		 EMG, CSF 31 IVIG
1 GC
3 no treat		 Mild/moderate sequelae
7 Dharmarajan et. al. [10] 53 NA Non severe VIII 53 Audiometry NA NA
8 Travi et. al. [11] 6 NA NA GBS 6 CSF NA NA
9 Keddie et. al. [12] 13 11 (85) NA AIDP 7
GBS 5		 MFS 1 CSF±EMG 9 IVIG
4 no treat		 1 death
10 Hinduja et. al [13] 13 8 (61.5) NA Dysautonomia 13 FESC/HESC NA NA
11 Delome et. al. [14] 9 NA NA GBS 5 VI 1
I 1
III 1
XII 2		 EMG, CSF NA NA
12 Fragiel et. al. [15] 11 6 (54.5) NA AIDP 7
AMAN 2
PNP 1		 VII 1 CSF NA 0 mortality
13 Meppiel et. al. [16] 19 13 (68) 5 severe AIDP 15
MNM 1
 III 2
VII 1		 EMG, CSF, MRI 14 IVIG 1 mortality
3 full resolution
14 Tony A et. al. [17] 107 51 (48) NA GBS 107 NA NA NA
15 Viola et. al. [18] 77 42 (54.5) NA VIII 77 NA NA NA
16 Rifino et. al. [19] 17 13 (76) Severe GBS 17 13 V/VIII NA NA NA
17 Khedr et. al. [20] 35 NA NA GBS 4 I 9
VII 2
I+VII 22		 NA NA NA
18 Koh et. al. [21] 11 11 (100) 2 severe AMSAN 1
Dysautonomia 5		 VII 5 EMG, autonomic function tests GC/PLEX 2 improved
19 Karadaş et. al. [22] 18 NA NA GBS 1 8 V
9 IX		 NA NA NA
Open in a new tab

Abbreviations: F–female, M–male, PNS–peripheral nervous system, CN–cranial nerves, CSF–cerebrospinal fluid, AIDP–acute inflammatory demyelinating polyneuropathy, AMAN–acute motor axonal neuropathy, AMSAN–acute motor and sensitive axonal neuropathy, GBS–Guillain Barre syndrome, MFS—Miller Fisher syndrome, PNP–polyneuropathy, MNM–mononeuritis multiplex, GC—glucocorticoids, PLEX–plasma exchange, IVIG–intravenous immunoglobulins, EMG–electromyography, FESC–feet electrochemical skin conductance, HESC–hand electrochemical skin conductance, I–olfactory nerve, II–optic nerve, III–oculomotor nerve, IV–trochlear nerve, V–trigeminal nerve, VI–abducens nerve, VII–facial nerve, VIII–vestibulocochlear nerve, IX–glossopharyngeal nerve, X–vagus nerve, XI–accessory nerve, XII–hypoglossal nerve, NA–not available.

The gender was known for 910 patients and 513(51.1%) were male. Four hundred and twenty-nine (42.7%) patients had non-severe forms of COVID-19, 133 (13.2%) had severe forms of disease, while in 334 (33.3%) patients the disease form was not reported.

For the neurological outcome we assumed the outcome reported in the original articles.

Descriptive data of the cranial nerve involvement is presented in Table 2.

Table 2. Types of cranial nerves involvement in patients with COVID-19.

Cranial nerve (CN) Studies that mention CN involvement Pooled events Isolated CN involvement CN + PNS Involvement
195 957 (%) 805 (%) 152 (%)
I (olphactory) 11 154 (16.1) 151 (18.7) 2 (1.3) I + GBS, 1 I + MNM, 1
II (optic) 10 24 (2.5) 23 (2.8) 1 (0.6) II + GBS
III + IV + VI (oculomotor, trochlear, abducens) 29 56 (5.8) 38 (4.7) 18 (11.8) III + IV + VI + GBS, 17 III + IV + VI + dysautonomia, 1
V(trigeminal) 8 41(4.3) 15 (1.9 26 (17.1) V+ GBS, 25 V+ dysautonomia, 1
VII (facial) 70 261 (27.3) 190 (23.6) 71 (46.7) VII+ GBS, 70 VII+ dysautonomia, 1
VIII (vestibulo-cochlear) 25 243 (25.4) 241 (29.7) 2 (1.3) VIII+ GBS, 1 VIII+ dysautonomia, 1
IX (glossopharingeal), 16 99 (10.3) 86 (10.7) 13 (8.5) IX + GBS
X (vagus) 17 49 (5.1) 35 (4.3) 14 (9.2) X + GBS
XI (accessory) 3 20 (2.1) 17 (2.1) 3 (1.9) XI + GBS
XII (hypoglossal) 6 11 (1.1) 9 (1.1) 2 (1.3) XII + GBS
Open in a new tab

Abbreviations: N–number, CN–cranial nerves, PNS–peripheral nervous system, GBS–Guillain Barre Syndrome, MNM–mononeuritis multiplex

The facial nerve (VII) was the most frequently involved (27.3%), followed by the vestibulo cochlear nerve, VIII (25.4%) and olphactory, I (16.1%) The least affected by COVID-19 was the hypoglossal nerve, XII (1.1%). In patients with both types of neurological involvement, GBS spectrum was the most common type of PNS involvement, in 147/152 (96.7%) reported cases. Dysautonomia and MNM were only rarely reported. Vestibulo-cochlear nerve (VIII) involvement was most often isolated, in contrast with nerves III (oculomotors), IV (trochlear), VI (abducens), VII (facial), IX (glossopharyngeal) and X (vagus), which were affected also in combination with different types of PNS. The trigeminal nerve (V) was the only CN mostly involved in combination with PNS findings rather than isolated. Even though we did not include patients with isolated anosmia, involvement of the first CN was found in combination with other CN, rather than associated with other PNS findings. From those studies reporting on patients with PNS involvement, unclassified Guillain Barre syndrome (uGBS) was the most frequently encountered, in more than 50% of the cases, in both isolated and PNS + CN involvement, followed by AIDP and dysautonomia (Table 3).

Table 3. Type of PNS involvement in patients with COVID-19.

Type of PNS involvement Studies Pooled events Isolated PNS involvement N(%) PNS + CN involvement N(%)
183 515(%) 350 (68) 165 (32)
uGBS, 75 273 (53) 183 (52.3) 90 (54.5)
AIDP 37 99 (19.2) 62 (17.7) 38 (10.8)
AMAN 13 13 (2.5) 9 (2.6) 4 (1.1)
AMSAN 19 31 (5.6) 25 (7.1) 6 (1.7)
MFS 13 18 (3.5) - 18 (5.1)
MNM 5 14 (2.7) 11 (3.1) 3 (1.8)
Dysautonomia 8 56 (10.9) 52 (14.8) 4 (2.4)
Others 13 10 (1.9) 8 (2.3) 2 (1.2)
Open in a new tab

Abbreviations: uGBS–unclassified Guillain Barre Syndrome, acute inflammatory demyelinating polyneuropathy, AMAN–acute motor axonal neuropathy, AMSAN–acute motor and sensitive axonal neuropathy, MFS–Miller Fischer Syndrome, MNM–mononeuritis multiplex.

The pharyngo-cervical-brachial form of GBS was the rarest one as it was found in only one patient [23]. Most cases of GBS were diagnosed using clinical criteria and/or cerebrospinal fluid (CSF) analysis.

Several patients with mononeuritis or mononeuritis multiplex were reported, usually involving the motor part of the sciatic nerve. Other types of peripheral nerve involvement were rare. We identified two cases of post infectious carpal tunnel syndrome, raising concerns about cross reaction between SARS-CoV- 2 antigens and synovial cells [24]. Parsonage Turner was also found in a few patients, appearing in one case during the first days of hospitalization for COVID-19 [25]. Another patient developed the symptoms after four months of persistent dyspnea due to COVID-19, hypothesizing diaphragmatic involvement prior to neuralgic amyotrophia [26]. A few cases of peripheral polyneuropathy that did not meet the GBS criteria for various reasons were identified; one patient responded well to plasma exchange, though, suggesting an immunologic mechanism [27–29]. In one case the neurological symptoms were self-limited but preceded the respiratory symptoms due to COVID-19 by a few days [27].

Here we present the results of the qualitative analysis of the articles reporting individual patient data. Data is shown in Table 4. The articles included in this synthesis are available in S1 Table.

Table 4. Comparative clinical data according to different types of neurological involvement.

Number of patients, N = 328 CN involvement N = 102 (%) PNS involvement N = 161 (%) CN + PNS involvement N = 65 (%) p value Missing data N (%)
Male sex 55 (53.9) 91 (56.5) 39/63 (61.9) .63 2 (0.6)
Age, mean ± SD 46.2 ± 17.1 52.9 ±15.1 51.6 ± 15 .003 0
Severe COVID-19 25/101 (24.8) 59/158 (37.3) 22/63 (34.9) .1 6(1.8
Duration between disease onset and neurological symptoms (days), median (range) 8 (0–90) 13.5 (0–122) 13.5 (0–42) .06 65 (19.8)
Level of patient care Outpatient 35/87 (40.2) 15/115 (13) 5/60 (8.3) < .001 66 (20.1)
Normal ward 33/87 (37.9) 47/115 (40.9) 28/60 (46.7)
ICU 19/87 (21.8) 53/115 (46.1) 27/60 (45)
Treatment GC 45 (44.1) 12 (7.5) 16/65 (24.6) < .001 0
IVIG 38 (37.3) 81 (50.3) 17/65 (26.2) .002
PLEX 0 (0) 19 (11.8) 5/65 (7.7) .002
No treatment 11 (10.8) 15 (9.3) 16 (24.6) .006
Others 3 (2.9) 5 (3.1) 1 (1.5) .8
Outcome Recovered completely 24/95 (25.3) 24/123 (19.5) 12/59 (20.3) .1 51 (15.5)
Mild/moderate sequelae 52/95 (54.7) 83/123 (67.5) 40/59 (67.8)
No improvement 17/95 (17.9) 10/123 (8.1) 4/59 (6.8)
Non-survivors 2/95 (2.1) 6/123 (4.9) 3/59 (5.1)
Open in a new tab

Abreviations: CN–cranial nerves, PNS–peripheral nervous system, ICU–intensive care unit, GC–glucocorticoids, IVIG–intravenous immunoglobulins, PLEX–plasma exchange

Patients with CN involvement were younger (mean of 46.2 ±17.1 years, p = .003) than those with either isolated PNS involvement or both types of neurological involvement (mean of 52.9 ±15.1 and 51.6±15). In terms of patient care, those with CN involvement were mostly treated as outpatients compared to those with PNS involvement (either isolated or in conjunction with CN involvement), that were more likely to be hospitalized and/or ICU stay (p < .001). Patients with PNS involvement were more likely to receive intravenous immunoglobulins (p = .002) or plasma exchange (p = .002) compared to patients with isolated CN involvement that received mostly glucocorticoids (p< .001). Also, we found no statistically significant differences regarding COVID-19 disease severity among all three groups of patients, with severe forms of disease in less than 40% in all categories. When comparing the groups in Table 4, duration between disease onset and the neurological symptoms was shorter for the CN groups– 8 (0–90) days, versus 13.5 (0–122) and 13. 5 (0–42) respectively (p = .06).

In Fig 2 we represented the overlapping between the PNS and CN involvement emphasizing the most commonly affected CN (I, VII, VIII).

Fig 2. Peripheral nervous system involvement; PNS–peripheral nervous system, PNS+CN–peripheral nervous system and cranial nerves, I–olfactory nerve, VII–facial nerve, VIII–vestibulo-cochlear nerve.

Fig 2

Open in a new tab

Discussions

Mechanisms of neurological involvement in SARS-CoV-2 infection

In this systematic review we identified various peripheral nerve manifestations, ranging from the classic form of GBS to a wide range of CN symptoms. Regarding the mechanisms of the neurological involvement, two main theories have been postulated: the neurotropism and neuroinvasion of the SARS-CoV-2 virus on the one hand, and the dysimmune response to the virus on the other [5–7, 9–13, 15–23, 25–57].

SARS-CoV-2 enters the human cell via the angiotensin-converting enzyme 2 (ACE2) receptor using the spike proteins located on its surface. The ACE2 receptor is present on the surface of neurons, glia, endothelial cells. It is more concentrated in certain areas of the brain such as the brainstem, especially in the cardiovascular and respiratory regulation area, nucleus of the tractus solitarius, periventricular areas, etc. [58].

The pathway for the viral neuroinvasion is considered to be the peripheral nerve terminals. The olfactory nerve route is the most cited, but this issue is still under debate. The nasal epithelium has a high concentration of ACE2 receptors, explaining the anosmia and allowing the virus to enter the pseudounipolar neurons. From here, the virus is transported trans synaptically, through the cribriform plate to the olfactory bulb and to the CNS. Another possible pathway is via the enteric nervous system, as there is proof that SARS-CoV2 can invade the enteric cells via the highly expressed ACE2 receptors in the small intestine. At this level the virus can be transported to the CNS via both antero- and retro-grade transport [1, 39, 58].

Song et. al. studied the effects of the novel coronavirus on neural tissues of both human and mouse origin, suggesting that the neurological symptoms are a result of direct viral invasion. It appears that the neuroinvasive characteristics of SARS-CoV-2 are different from other neurotropic viruses (like rabies, or HSV) as it does not induce a lymphocyte infiltration around the positive viral staining areas [59].

SARS-CoV-2 induces also an important inflammatory response, especially in patients with severe disease, known as the “cytokine storm”. As a consequence of the innate immune response, an excessive release of pro-inflammatory cytokines (IL-1, IL-6, IL-8, IL-12, TNF-α, interferons, CXCL-10, MCP-1, MIP-1α, G-CSF and also GM-CSF) into the bloodstream, will lead to multiple tissue and organ damage (MODS). This inflammatory response may also trigger a disruption in the blood-brain barrier, causing a hematogenous spread of the virus into the CNS. At the same time, the neuro-immune pathway functions bidirectionally, leading to the inflammatory reflex: the afferent neurons of the vagus nerve respond to immune signals in the periphery and the efferent neurons regulate the pro-inflammatory cytokines release and will also orchestrate the systemic inflammatory response [1, 38, 55].

Since the beginning of the vaccination campaign, controversies regarding association between GBS and other neuropathies on one hand, and the SARS-CoV-2 vaccines on the other have arisen. To date, no causal relationship has been clearly established, as there may be a coincidental association. Although not the topic of our review, potential association between SARS-CoV-2 vaccines and different immune mediated neuropathies should be more thoroughly analyzed.

PNS involvement in SARS-CoV-2 infection

GBS is usually a post infectious, immune-mediated peripheral nervous system disease, caused by a dysimmune response to an infectious agent, but in COVID-19 theories about para-infectious manifestations are emerging. Khan et. al. identified the presence of SARS-CoV-2 RNA in the CSF of a GBS patient, raising questions about the direct involvement of the virus in GBS physiopathology. In the same case series, there is a patient who developed AIDP symptoms one day after COVID-19 symptoms, but PCR for SARS-CoV-2 was negative in the CSF. The same pattern of para-infectious GBS was also observed in other case reports [20, 36, 37]. On the other hand, in a study comparing the COVID-19 associated GBS incidence with the general GBS incidence for the same period a year before the pandemic, no epidemiological and phenotypical association between SARS-CoV-2 and GBS was found [12]. The majority of patients who developed GBS secondary to COVID-19 follows the known disease pattern: ascending neurological deficits (sensorial, motor or both) few weeks after an infection. There are still questions to answer regarding the physiopathology in patients who develop GBS symptoms prior to or immediately after presenting other SARS-CoV-2 manifestations, as the RNA presence in the CSF is a rare finding, even in this category [35]. In a multicentric study from India patients with post infectious (after four weeks) GBS had a better outcome than those with para infectious GBS [9].

All types of PNS manifestations were found isolated in 60% to more than 90% of reported events, rather than associated with CN involvement. Symptoms of dysautonomia are varied, ranging from sudomotor dysfunction to tachycardia and orthostatic hypotension. The mechanism differs, as sudomotor dysfunction is the result of small fiber neuropathy, and tachycardia and orthostatic hypotension could be the result of the nucleus tractus solitarius dysfunction due to SARS-CoV-2 neuroinvasion. In one case a rare finding of sudomotor dysfunction preceding AMAN was reported [13, 34].

MNM is usually associated with some types of vasculitis, so SARS-CoV-2 may cause MNM by a combined mechanism of dysimmunity and microthrombi of the vasa nervorum [31–33]. A similar cause was hypothesized in a patient who presented brachial plexopathy preceded by purpuric rash on his arm during hospitalization for COVID-19 [30]. He developed the symptoms after at least 12 days since the onset of COVID-19 symptoms, so an immune mediated cause is more plausible.

Most patients with PNS manifestations presented with a non-severe form of COVID-19 and had a good neurological outcome although the majority remained with mild to moderate sequelae [9]. Patients with GBS spectrum were mostly treated with IVIG and plasma exchange [60]. MFS, part of the GBS spectrum involving the CN along with ataxia and hyporeflexia, was also treated with IVIG with good neurological outcome, some patients remaining only with hyporeflexia [9, 12, 61–68]. In one case the symptoms resolved spontaneously [69]. The same spontaneous resolution was found in the case of pharyngo-cervical-brachial form of GBS [23].

Of the two patients with carpal tunnel syndrome, one remained with mild paresthesia in the fifth finger, although both underwent decompressive surgery [24]. The patients with Parsonage Turner syndrome, although they received glucocorticoids and IVIG, remained with significant motor deficits [25, 26]. The patients with MNM remained mostly with fatigability and didn’t need any neurological treatment [33]. In a MNM case complicated with Kawasaki disease and myocarditis, the patient had a good outcome but with persistent bilateral foot drop four months later after treatment with rituximab, cyclophosphamide and IVIG [31]. Patients with dysautonomia received no specific treatment [13].

CN involvement in SARS-CoV-2 infection

The CN were affected either in isolation or associated with the peripheral nerves. The facial nerve was the most affected CN overall and in association with other peripheral neuropathies, but it was still more frequently affected isolated. Whether this is the result of direct nerve invasion, or it is also the result of an inflammatory response, it remains to be settled. Also, a reactivation of herpes simplex virus or varicella-zoster virus cannot be ruled out, as COVID-19 can induce a state of immunosuppression. Codeluppi et.al. observed a 21% raise in peripheral facial nerve palsy in the pandemic compared to the same period of the previous year, as well as younger age of patients [51]. Similar findings were reported by others. [7, 35].

The vestibulocochlear nerve was the second most affected nerve and was mostly found affected in isolation. The most common symptoms were sudden sensory-neural hearing loss (SSNHL), tinnitus and vertigo. The majority of reported cases presented with unilateral involvement, but in one case series bilateral involvement was more frequent. If unilateral SSNHL is usually a sign of direct viral invasion as is the case with other viruses (HSV, CMV), bilateral symptomatology is more prone to being the consequence of a systemic response, such as inflammation or vasculitis. In a study conducted by Dharmarajan et. al. 48% of the patients with audiometric proof of SSNHL had no symptom of SSNHL, suggesting an even larger potential number of COVID-19 patients with subclinical vestibulo-cochlear nerve involvement [4, 10].

The oculomotors, the vagus, glossopharyngeal, accessory and hypoglossal nerves were also more frequently affected isolated rather than associated with other types of peripheral neuropathies. The trigeminal nerve is the only CN that was more often associated with peripheral neuropathies, rather than in isolation. The least affected CN overall was the hypoglossal nerve (XII). In one prospective observational study it was found that the sensory functions of the nerves were more affected than the motor ones [6].

Even though our study did not include patients that presented with isolated anosmia, it was most likely associated with other CN manifestations rather than peripheral neuropathies. In a study measuring the olfactory cleft it was found that larger width and volume of the olfactory cleft was a predisposing factor for anosmia in COVID-19 patients, as it may result in more prompt nasal immune response and facilitate access to the olfactory bulb [8].

Patients with CN involvement had mostly non severe forms of COVID-19 and received glucocorticoids either locally, or systemically, or both, with various results. For example, some patients with SSNHL recovered their hearing partially, while others had mild or no improvement, but early identification and treatment was linked to better results [4, 10, 18]. Isolated facial palsy was also treated with glucocorticoids, with good results. Patients with facial diplegia and GBS received mostly IVIG with symptoms resolution in various degrees. [51, 70–72].

Our quantitative synthesis showed that patients with isolated CN involvement were more likely to be outpatients, while patients with isolated PNS involvement were more prone to staying in the ICU. We should take into consideration that most studies did not mention the reason for the ICU stay–either the severe type of disease, or the neurological involvement, but given the fact that GBS is usually treated in an ICU, this may be a reasonable assumption.

Regarding treatment, patients with isolated CN involvement received mostly glucocorticoids, either systemically, locally, or both, while patients with PNS involvement were more likely to receive IV immunoglobulins or plasma exchange, similar to the standard treatment of these findings secondary to other etiologies [73].

There was no difference in sex distribution between groups, with male patients representing over 50% of patients in all three categories. Although the difference was not significant, patients with CN involvement had a shorter period between disease onset and neurological symptoms than the other two groups, suggesting a possible increased susceptibility of the CN to either direct neuroinvasion or to the inflammatory mechanism. The outcome was mostly favorable, the majority of patients in all three categories remaining with mild and moderate neurologic sequelae. A small number of patients died, but it’s difficult to say if the cause was the neurological involvement or the evolution of the COVID-19 disease. All three categories of patients were mostly associated with a non-severe type of COVID-19 disease. Patients with CN involvement were more likely to have a complete recovery compared to those with PNS involvement (isolated or PNS + CN involvement) therefore, the outcome could be related more to the neurologic involvement.

Our evidence synthesis of CN and PNS involvement by SARS-CoV-2 infection provided a comprehensive description of both the diverse clinical scenarios and associated pathophysiological mechanisms. The strengths of our study include also a review of potential treatments and associated outcomes of patients with CN and PNS manifestations associated with COVID-19, as a result of a secondary performed analysis between different types of neurological involvement.

There are several important limitations to this review. First of all, most articles were case reports and case series, and only few prospective studies were identified. Second, there was a significant number of cases of unclassified GBS as the access to diagnostic tools was limited during the pandemic. Also, neurological findings in patients with severe COVID-19 may not have been sufficiently reported because of focusing mainly on COVID-19 and death before any neurological investigations could be made, leading to an underestimation. On the other hand, outpatients with mild neurological symptoms and mild COVID-19 may not have presented for care or data may not have been reported.

Many patients were lost to follow up, therefore the data available for the outcome may be biased.

However, at this time point, insufficient data is available on this topic and further research needs to be assessed in order to generate clear clinical correlations and therapeutic decision-making strategies.

Conclusions

In conclusion, PNS involvement in COVID-19 may be an important cause of hospitalization and post COVID-19 sequelae, increasing the burden on the healthcare systems, even though they are usually associated with mild and moderate forms of disease. Additional studies following consecutive patients with various severities of COVID 19 forms are needed in order to evaluate the incidence of neurological events and to identify the risk factors. Randomized clinical trials are also needed to assess different interventions for the management of neurological manifestations.

Supporting information

S1 Fig. PRISMA 2009 checklist.

(TIF)

Click here for additional data file. (1.3MB, tif)
S1 Table. Characteristics of patients included in the qualitative analysis.

(DOCX)

Click here for additional data file. (408.6KB, docx)

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.DosSantos MF, Devalle S, Aran V, Capra D, Roque NR, Coelho-Aguiar J de M, et al. Neuromechanisms of SARS-CoV-2: A Review. Front Neuroanat. 2020. Jun 16;14. doi: 10.3389/fnana.2020.00037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020. Jun 1;77(6):683. doi: 10.1001/jamaneurol.2020.1127 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Kajumba MM, Kolls BJ, Koltai DC, Kaddumukasa M, Kaddumukasa M, Laskowitz DT. COVID-19-Associated Guillain-Barre Syndrome: Atypical Para-infectious Profile, Symptom Overlap, and Increased Risk of Severe Neurological Complications. SN Compr Clin Med. 2020. Dec 21;2(12):2702–14. doi: 10.1007/s42399-020-00646-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Yaseen NK, Al-Ani RM, Ali Rashid R. COVID-19-related sudden sensorineural hearing loss. Qatar Med J. 2021. Dec 13;2021(3). doi: 10.5339/qmj.2021.58 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Foresti C, Servalli MC, Frigeni B, Rifino N, Storti B, Gritti P, et al. COVID‐19 provoking Guillain–Barré syndrome: The Bergamo case series. Eur J Neurol. 2021. Oct 14;28(10). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Doblan A, Kaplama ME, Ak S, Basmacı N, Tarini EZ, Göktaş ŞE, et al. Cranial nerve involvement in COVID-19. Am J Otolaryngol. 2021. Sep;42(5):102999. doi: 10.1016/j.amjoto.2021.102999 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Ozdemir I, Kocamıs SI. Acute Lagophthalmos due to Bell’s Palsy could be a Sign of COVID-19. Neuro-Ophthalmology. 2021. Sep 3;45(5):309–12. doi: 10.1080/01658107.2021.1909074 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Altundag A, Yıldırım D, Tekcan Sanli DE, Cayonu M, Kandemirli SG, Sanli AN, et al. Olfactory Cleft Measurements and COVID-19–Related Anosmia. Otolaryngology–Head and Neck Surgery. 2021. Jun 13;164(6):1337–44. doi: 10.1177/0194599820965920 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Dhamne M, Benny R, Singh R, Pande A, Agarwal P, Wagh S, et al. Guillian—Barre’ syndrome in patients with SARS-CoV-2: A multicentric study from Maharashtra, India. Ann Indian Acad Neurol. 2021;24(3):339. doi: 10.4103/aian.AIAN_1303_20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Dharmarajan S, Bharathi MB, Sivapuram K, Prakash BG, Madhan S, Madhu A, et al. Hearing Loss-a Camouflaged Manifestation of COVID 19 Infection. Indian Journal of Otolaryngology and Head & Neck Surgery. 2021. Dec 10;73(4):494–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Travi G, Rossotti R, Merli M, D’Amico F, Chiappetta S, Giussani G, et al. Neurological manifestations in patients hospitalized with COVID‐19: A retrospective analysis from a large cohort in Northern Italy. European Journal of Neuroscience. 2021. Apr 24;53(8):2912–22. doi: 10.1111/ejn.15159 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Keddie S, Pakpoor J, Mousele C, Pipis M, Machado PM, Foster M, et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain. 2021. Mar 3;144(2):682–93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Hinduja A, Moutairou A, Calvet JH. Sudomotor dysfunction in patients recovered from COVID-19. Neurophysiologie Clinique. 2021. Mar;51(2):193–6. doi: 10.1016/j.neucli.2021.01.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Delorme C, Houot M, Rosso C, Carvalho S, Nedelec T, Maatoug R, et al. The wide spectrum of COVID-19 neuropsychiatric complications within a multidisciplinary centre. Brain Commun. 2021. Jul 1;3(3). doi: 10.1093/braincomms/fcab135 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Fragiel M, Miró Ò, Llorens P, Jiménez S, Piñera P, Burillo G, et al. Incidence, clinical, risk factors and outcomes of Guillain‐Barré in Covid‐19. Ann Neurol. 2021. Mar 28;89(3):598–603. [DOI] [PubMed] [Google Scholar]
  • 16.Meppiel E, Peiffer-Smadja N, Maury A, Bekri I, Delorme C, Desestret V, et al. Neurologic manifestations associated with COVID-19: a multicentre registry. Clinical Microbiology and Infection. 2021. Mar;27(3):458–66. doi: 10.1016/j.cmi.2020.11.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Tony AA, Ahmed SB, Tony EA, Maklad S, Elnakeeb I, Amin MM. Predictors of Neurological Presentations of COVID-19 Infected Patients in South Egypt, Aswan Governorate: A Single Center Study. Neuropsychiatr Dis Treat. 2021. Dec;Volume 17:3471–82. doi: 10.2147/NDT.S333109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Viola P, Ralli M, Pisani D, Malanga D, Sculco D, Messina L, et al. Tinnitus and equilibrium disorders in COVID-19 patients: preliminary results. European Archives of Oto-Rhino-Laryngology. 2021. Oct 23;278(10):3725–30. doi: 10.1007/s00405-020-06440-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Rifino N, Censori B, Agazzi E, Alimonti D, Bonito V, Camera G, et al. Neurologic manifestations in 1760 COVID-19 patients admitted to Papa Giovanni XXIII Hospital, Bergamo, Italy. J Neurol. 2021. Jul 7;268(7):2331–8. doi: 10.1007/s00415-020-10251-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Khedr EM, Shoyb A, Mohamed KO, Karim AA, Saber M. Case Report: Guillain–Barré Syndrome Associated With COVID-19. Front Neurol. 2021. Jun 22;12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Koh JS, de Silva DA, Quek AML, Chiew HJ, Tu TM, Seet CYH, et al. Neurology of COVID-19 in Singapore. J Neurol Sci. 2020. Nov;418:117118. doi: 10.1016/j.jns.2020.117118 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Karadaş Ö, Öztürk B, Sonkaya AR. A prospective clinical study of detailed neurological manifestations in patients with COVID-19. Neurological Sciences. 2020. Aug 25;41(8):1991–5. doi: 10.1007/s10072-020-04547-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Liberatore G, de Santis T, Doneddu PE, Gentile F, Albanese A, Nobile-Orazio E. Clinical Reasoning: A case of COVID-19–associated pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Neurology. 2020. Nov 24;95(21):978–83. [DOI] [PubMed] [Google Scholar]
  • 24.Roncati L, Gianotti G, Gravina D, Attolini G, Zanelli G, Rosa N della, et al. Carpal, cubital or tarsal tunnel syndrome after SARS-CoV-2 infection: A causal link? Med Hypotheses. 2021. Aug;153:110638. doi: 10.1016/j.mehy.2021.110638 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Ismail II, Abdelnabi EA, Al-Hashel JY, Alroughani R, Ahmed SF. Neuralgic amyotrophy associated with COVID-19 infection: a case report and review of the literature. Neurological Sciences. 2021. Jun 20;42(6):2161–5. doi: 10.1007/s10072-021-05197-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Viatgé T, Noel-Savina E, Prévot G, Faviez G, Plat G, de Boissezon X, et al. Syndrome de Parsonage-Turner compliquant une infection sévère à SARS-CoV-2. Rev Mal Respir. 2021. Oct;38(8):853–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Abdelnour L, Eltahir Abdalla M, Babiker S. COVID 19 infection presenting as motor peripheral neuropathy. Journal of the Formosan Medical Association. 2020. Jun;119(6):1119–20. doi: 10.1016/j.jfma.2020.04.024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Faqihi F, Alharthy A, Memish ZA, Kutsogiannis DJ, Brindley PG, Karakitsos D. Peripheral neuropathy in severe COVID‐19 resolved with therapeutic plasma exchange. Clin Case Rep. 2020. Dec 7;8(12):3233–8. doi: 10.1002/ccr3.3397 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Bureau BL, Obeidat A, Dhariwal MS, Jha P. Peripheral Neuropathy as a Complication of SARS-Cov-2. Cureus. 2020. Nov 12; doi: 10.7759/cureus.11452 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Han CY, Tarr AM, Gewirtz AN, Kaunzner UW, Roy-Burman P, Cutler TS, et al. Brachial plexopathy as a complication of COVID-19. BMJ Case Rep. 2021. Mar 25;14(3):e237459. doi: 10.1136/bcr-2020-237459 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Othenin-Girard A, Regamey J, Lamoth F, Horisberger A, Glampedakis E, Epiney JB, et al. Multisystem inflammatory syndrome with refractory cardiogenic shock due to acute myocarditis and mononeuritis multiplex after SARS-CoV-2 infection in an adult. Swiss Med Wkly. 2020. Nov 11; doi: 10.4414/smw.2020.20387 [DOI] [PubMed] [Google Scholar]
  • 32.Acharya S, Thibault M, Lee J, Taha O, Morpurgo AJ, Kshetree BK, et al. COVID-19-Induced Left Sciatic Neuropathy Requiring Prolonged Physical Medicine and Rehabilitation. Cureus. 2021. Jun 21; doi: 10.7759/cureus.15803 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Daia C, Toader C, Scheau C, Onose G. Motor demyelinating tibial neuropathy in COVID-19. Journal of the Formosan Medical Association. 2021. Nov;120(11):2032–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Ghosh R, Roy D, Sengupta S, Benito-León J. Autonomic dysfunction heralding acute motor axonal neuropathy in COVID-19. J Neurovirol. 2020. Dec 11;26(6):964–6. doi: 10.1007/s13365-020-00908-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Andalib S, Biller J, di Napoli M, Moghimi N, McCullough LD, Rubinos CA, et al. Peripheral Nervous System Manifestations Associated with COVID-19. Curr Neurol Neurosci Rep. 2021. Mar 14;21(3):9. doi: 10.1007/s11910-021-01102-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Svačina MKR, Kohle F, Sprenger A, Lehmann HC. Could symptom overlap of COVID-19 and Guillain–Barré syndrome mask an epidemiological association? J Neurol. 2021. Oct 17;268(10):3595–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Khan F, Sharma P, Pandey S, Sharma D, V. V, Kumar N, et al. COVID‐19‐associated Guillain‐Barre syndrome: Postinfectious alone or neuroinvasive too? J Med Virol. 2021. Oct 6;93(10):6045–9. doi: 10.1002/jmv.27159 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Wong RSY. The SARS-CoV-2 Outbreak: an Epidemiological and Clinical Perspective. SN Compr Clin Med. 2020. Nov 29;2(11):1983–91. doi: 10.1007/s42399-020-00546-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Lamers MM, Beumer J, van der Vaart J, Knoops K, Puschhof J, Breugem TI, et al. SARS-CoV-2 productively infects human gut enterocytes. Science (1979). 2020. Jul 3;369(6499):50–4. doi: 10.1126/science.abc1669 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Nejad JH, Heiat M, Hosseini MJ, Allahyari F, Lashkari A, Torabi R, et al. Guillain-Barré syndrome associated with COVID-19: a case report study. J Neurovirol. 2021. Oct 27;27(5):802–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Koca A, Talan L, Şahin T, Çınar G, Evren E, Karahan ZC, et al. An unusual course of SARS-CoV-2 infection: Challenging diagnosis of Guillain-Barré Syndrome. Tuberk Toraks. 2021. Jun 15;69(2):242–6. [DOI] [PubMed] [Google Scholar]
  • 42.Mehrpour M, Arab M, Hadavand F, Khalafi M, Khalafi M. A case report of Guillain–Barré syndrome in a pregnant woman infected by COVID-19. Acta Neurol Belg. 2021. Aug 3;121(4):1079–80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.d’Orsi G, Sica S, Maiorano A, Melchionda D, Lalla A, Montemurro L, et al. Guillain-Barré syndrome as only manifestation of COVID-19 infection. Clin Neurol Neurosurg. 2021. Aug;207:106775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.COVID-19-induced Guillain-Barre Syndrome: A Rare Complication of SARS-CoV-2 Infection. Journal of the College of Physicians and Surgeons Pakistan. 2021. Jul 1;31(2):S123–4. doi: 10.29271/jcpsp.2021.Supp2.S123 [DOI] [PubMed] [Google Scholar]
  • 45.Masuccio FG, Barra M, Claudio G, Claudio S. A rare case of acute motor axonal neuropathy and myelitis related to SARS-CoV-2 infection. J Neurol. 2021. Jul 17;268(7):2327–30. doi: 10.1007/s00415-020-10219-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Defabio AC, Scott TR, Stenberg RT, Simon EL. Guillain-Barré syndrome in a patient previously diagnosed with COVID-19. Am J Emerg Med. 2021. Jul;45:154–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Mehta S, Sunder A. Getting paralysed after COVID: Guillain–Barre syndrome. J Family Med Prim Care. 2021;10(7):2706. doi: 10.4103/jfmpc.jfmpc_2454_20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Maramattom B, Zachariah A, Meleth H, Zachariah Z, Mathew K. Post Covid-19 guillain barre syndrome. Ann Indian Acad Neurol. 2021;0(0):0. doi: 10.4103/aian.AIAN_853_20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Chowdhury FUH, Paul S, Aman S, Haque A, Rafiquzzaman M, Rahman M, et al. A Middle-Aged Man Presented with Quadriparesis during COVID-19 Pandemic. Case Rep Neurol. 2021. Aug 18;13(2):529–34. doi: 10.1159/000517914 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Shouman K, Vanichkachorn G, Cheshire WP, Suarez MD, Shelly S, Lamotte GJ, et al. Autonomic dysfunction following COVID-19 infection: an early experience. Clinical Autonomic Research. 2021. Jun 16;31(3):385–94. doi: 10.1007/s10286-021-00803-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Codeluppi L, Venturelli F, Rossi J, Fasano A, Toschi G, Pacillo F, et al. Facial palsy during the COVID‐19 pandemic. Brain Behav. 2021. Jan 7;11(1). doi: 10.1002/brb3.1939 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, Sánchez-Larsen Á, Layos-Romero A, García-García J, et al. Neurologic manifestations in hospitalized patients with COVID-19. Neurology. 2020. Aug 25;95(8):e1060–70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Khedr EM, Abo-Elfetoh N, Deaf E, Hassan HM, Amin MT, Soliman RK, et al. Surveillance Study of Acute Neurological Manifestations among 439 Egyptian Patients with COVID-19 in Assiut and Aswan University Hospitals. Neuroepidemiology. 2021;55(2):109–18. doi: 10.1159/000513647 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Siepmann T, Kitzler HH, Lueck C, Platzek I, Reichmann H, Barlinn K. Neuralgic amyotrophy following infection with SARS‐CoV ‐2. Muscle Nerve. 2020. Oct 10;62(4). [DOI] [PubMed] [Google Scholar]
  • 55.Guilmot A, Maldonado Slootjes S, Sellimi A, Bronchain M, Hanseeuw B, Belkhir L, et al. Immune-mediated neurological syndromes in SARS-CoV-2-infected patients. J Neurol. 2021. Mar 30;268(3):751–7. doi: 10.1007/s00415-020-10108-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Bax F, Lettieri C, Marini A, Pellitteri G, Surcinelli A, Valente M, et al. Clinical and neurophysiological characterization of muscular weakness in severe COVID-19. Neurological Sciences. 2021. Jun 23;42(6):2173–8. doi: 10.1007/s10072-021-05110-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Visco V, Vitale C, Rispoli A, Izzo C, Virtuoso N, Ferruzzi GJ, et al. Post-COVID-19 Syndrome: Involvement and Interactions between Respiratory, Cardiovascular and Nervous Systems. J Clin Med. 2022. Jan 20;11(3). doi: 10.3390/jcm11030524 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Tremblay ME, Madore C, Bordeleau M, Tian L, Verkhratsky A. Neuropathobiology of COVID-19: The Role for Glia. Front Cell Neurosci. 2020. Nov 11;14. doi: 10.3389/fncel.2020.592214 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Song E, Zhang C, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. Journal of Experimental Medicine. 2021. Mar 1;218(3). doi: 10.1084/jem.20202135 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Pelea T, Reuter U, Schmidt C, Laubinger R, Siegmund R, Walther BW. SARS-CoV-2 associated Guillain–Barré syndrome. J Neurol. 2021. Apr 8;268(4):1191–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Rana S, Lima AA, Chandra R, Valeriano J, Desai T, Freiberg W, et al. Novel Coronavirus (COVID-19)-Associated Guillain–Barré Syndrome: Case Report. J Clin Neuromuscul Dis. 2020. Jun;21(4):240–2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Lantos JE, Strauss SB, Lin E. COVID-19–Associated Miller Fisher Syndrome: MRI Findings. American Journal of Neuroradiology. 2020. Jul;41(7):1184–6. doi: 10.3174/ajnr.A6609 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Lowery MM, Taimur Malik M, Seemiller J, Tsai CS. Atypical Variant of Guillain Barre Syndrome in a Patient with COVID-19. The Journal of Critical Care Medicine. 2020. Nov 7;6(4):231–6. doi: 10.2478/jccm-2020-0038 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Manganotti P, Pesavento V, Buoite Stella A, Bonzi L, Campagnolo E, Bellavita G, et al. Miller Fisher syndrome diagnosis and treatment in a patient with SARS-CoV-2. J Neurovirol. 2020. Aug 11;26(4):605–6. doi: 10.1007/s13365-020-00858-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Senel M, Abu‐Rumeileh S, Michel D, Garibashvili T, Althaus K, Kassubek J, et al. Miller‐Fisher syndrome after COVID‐19: neurochemical markers as an early sign of nervous system involvement. Eur J Neurol. 2020. Nov 13;27(11):2378–80. doi: 10.1111/ene.14473 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Gutiérrez-Ortiz C, Méndez-Guerrero A, Rodrigo-Rey S, San Pedro-Murillo E, Bermejo-Guerrero L, Gordo-Mañas R, et al. Miller Fisher syndrome and polyneuritis cranialis in COVID-19. Neurology. 2020. Aug 4;95(5):e601–5. doi: 10.1212/WNL.0000000000009619 [DOI] [PubMed] [Google Scholar]
  • 67.Dinkin M, Gao V, Kahan J, Bobker S, Simonetto M, Wechsler P, et al. COVID-19 presenting with ophthalmoparesis from cranial nerve palsy. Neurology. 2020. Aug 4;95(5):221–3. doi: 10.1212/WNL.0000000000009700 [DOI] [PubMed] [Google Scholar]
  • 68.Assini A, Benedetti L, di Maio S, Schirinzi E, del Sette M. New clinical manifestation of COVID-19 related Guillain-Barrè syndrome highly responsive to intravenous immunoglobulins: two Italian cases. Neurological Sciences. 2020. Jul 28;41(7):1657–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Ray A. Miller Fisher syndrome and COVID-19: is there a link? BMJ Case Rep. 2020. Aug 11;13(8):e236419. doi: 10.1136/bcr-2020-236419 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Kerstens J, Deschuytere L, Schotsmans K, Maréchal E. Bilateral peripheral facial palsy following asymptomatic COVID-19 infection: a case report. Acta Neurol Belg. 2021. Jun 5;121(3):815–6. doi: 10.1007/s13760-021-01665-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Chen T, Briemberg HR. Guillain-Barre Syndrome with COVID-19. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 2022. May 12;49(3):414–5. doi: 10.1017/cjn.2021.108 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Garcia JJ, Turalde CW, Bagnas MA, Anlacan VM. Intravenous immunoglobulin in COVID-19 associated Guillain–Barré syndrome in pregnancy. BMJ Case Rep. 2021. May 11;14(5):e242365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Leonhard SE, Mandarakas MR, Gondim FAA, Bateman K, Ferreira MLB, Cornblath DR, et al. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nat Rev Neurol. 2019. Nov 20;15(11):671–83. [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Victor Daniel Miron

20 Feb 2023

PONE-D-22-25367Peripheral nervous system involvement associated with COVID-19. A systematic review of literaturePLOS ONE

Dear Dr. Hanganu,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: Although several articles have been published on this topic, your analysis is well structured. Please address the comments below. ==============================

Please submit your revised manuscript by Apr 06 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Victor Daniel Miron

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

The topic of the manuscript is of interest and although numerous case series/studies and meta-analyses have been published on this topic to date, this manuscript is clearly written but requires minor clarification:

- "SARS-CoV-2 is a respiratory virus," - I think here it should be rephrased. SARS-CoV-2 is a respiratory virus spread, but more recent studies show that the primary tropism of SARS-CoV-2 is not limited to the respiratory tract.

- In the introduction, I recommend deleting the sentence, as since the submission of this manuscript several reviews on this topic have been published: "By contrast, cranial nerve (CN) involvement and other PNS manifestations have not been extensively reviewed.".

- The methods are well described.

- Data on the time of onset of neurological manifestations in relation to the onset of the first symptoms of COVID-19 should be included. In the methods you state that you have taken into account these data regarding the time of onset. Is there any correlation between specific neurological manifestations and the time of onset?

- The discussion is well written.

- The abstract should be structured according to journal recommendations.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In this systematic review, the authors aim to investigate the characteristics, management and outcomes of patients with PNS manifestations. In my opinion, the authors achieved their objectives in this paper, so I recommend acceptance of this paper for publication.

Reviewer #2: The manuscript by Andreea-Raluca Hanganu et al. entitled “Peripheral nervous system involvement associated with COVID-19. A systematic review of literature” aimed to investigate the Characteristics, management and outcomes of patients with PNS, including the types and severity of cranial nerves (CN) involvement. The paper is well written and the discussion is honest in relation to the results. The abstract summarizes the general significance of the manuscript and the article leads some evidence to such point, but there are some major issues need to be addressed to improve the significance of the manuscript:

-Firstly, articles reporting neuropathies in patients vaccinated for SARS-CoV-2 within the previous three months in whom the neurological findings could have been attributed to vaccination were excluded. However, it would be interesting to include a paragraph on the vaccination/neuropathies relationship in the discussion.

- The authors should include some figures to make the text easier to read.

-Finally, the bibliography should be expanded; accordingly, this article should be cited:

Visco V, Vitale C, Rispoli A, Izzo C, Virtuoso N, Ferruzzi GJ, Santopietro M, Melfi A, Rusciano MR, Maglio A, Di Pietro P, Carrizzo A, Galasso G, Vatrella A, Vecchione C, Ciccarelli M. Post-COVID-19 Syndrome: Involvement and Interactions between Respiratory, Cardiovascular and Nervous Systems. J Clin Med. 2022 Jan 20;11(3):524. doi: 10.3390/jcm11030524. PMID: 35159974; PMCID: PMC8836767.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Apr 6;18(4):e0283827. doi: 10.1371/journal.pone.0283827.r002

Author response to Decision Letter 0

15 Mar 2023

Dear editor and reviewers,

Thank you for your valuable comments, allowing us to improve our manuscript.

Please find below the responses to the raised points:

1. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly: - see row 428

2. Please review your reference list to ensure that it is complete and correct.

As suggested, I revised the reference list and there is an article (doi: 10.7759/cureus.14391) that has been retracted because of fake peer review (doi:10.7759/cureus.8992). Thus, we redid the statistics but with no change in the final results. In the original manuscript the article was cited at no. 40. We also eliminated it from the Supplement Table 1.

3. "SARS-CoV-2 is a respiratory virus," - I think here it should be rephrased. SARS-CoV-2 is a respiratory virus spread, but more recent studies show that the primary tropism of SARS-CoV-2 is not limited to the respiratory tract – rephrased, see row 48

4. In the introduction, I recommend deleting the sentence, as since the submission of this manuscript several reviews on this topic have been published: "By contrast, cranial nerve (CN) involvement and other PNS manifestations have not been extensively reviewed." – deleted, see row 60

5. In the methods you state that you have taken into account these data regarding the time of onset. Is there any correlation between specific neurological manifestations and the time of onset? –

The results regarding the duration between disease onset and neurological manifestations were added in table no 4, row 237 and row 386. No statistical association was found.

6. The abstract should be structured according to journal recommendations.

We structured the abstract according to the recommendations: we described the main objective of the study, how the study was performed without details, summarized the most important results and their significance, we did not exceed 300 words and did not use citations.

We used abbreviations (which are not recommended but are not forbidden) because of the frequent use of the terms “cranial nerves” and “peripheral nervous system”. Not using abbreviations would have significantly limited our word count to present our results.

Did we understand correctly that you suggested deleting the subheadings?

7. However, it would be interesting to include a paragraph on the vaccination/ neuropathies relationship in the discussion – see row 282

8. The authors should include some figures to make the text easier to read – see Figure 2, row 242

9. Finally, the bibliography should be expanded; accordingly, this article should be cited: Visco V, Vitale C, Rispoli A, Izzo C, Virtuoso N, Ferruzzi GJ, Santopietro M, Melfi A, Rusciano MR, Maglio A, Di Pietro P, Carrizzo A, Galasso G, Vatrella A, Vecchione C, Ciccarelli M. Post-COVID-19 Syndrome: Involvement and Interactions between Respiratory, Cardiovascular and Nervous Systems. J Clin Med. 2022 Jan 20;11(3):524. doi: 10.3390/jcm11030524. PMID: 35159974; PMCID: PMC8836767 – see reference no 61

In addition, we made some changes at the PRISMA flow chart regarding the number of articles included in the qualitative synthesis because of a transcription error, and in the quantitative analysis because of the retracted paper.

Best wishes,

Andreea Hanganu

Attachment

Submitted filename: Response to Reviewers.docx

Click here for additional data file. (16.1KB, docx)

Decision Letter 1

Victor Daniel Miron

20 Mar 2023

Peripheral nervous system involvement associated with COVID-19. A systematic review of literature

PONE-D-22-25367R1

Dear Dr. Hanganu,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Victor Daniel Miron

Academic Editor

PLOS ONE

Acceptance letter

Victor Daniel Miron

28 Mar 2023

PONE-D-22-25367R1

Peripheral nervous system involvement associated with COVID-19. A systematic review of literature

Dear Dr. Hanganu:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Victor Daniel Miron

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. PRISMA 2009 checklist.

    (TIF)

    Click here for additional data file. (1.3MB, tif)
    S1 Table. Characteristics of patients included in the qualitative analysis.

    (DOCX)

    Click here for additional data file. (408.6KB, docx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    Click here for additional data file. (16.1KB, docx)

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.

    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES